="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

(1) Aggregate market value based on the closing price per share on Nasdaq on September 12, 2024. (2) Shares outstanding as of September 12, 2024.

Date of Notice

09/13/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

11/07/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Alejandra Carvajal, as attorney-in-fact for Martin H. Huber, Jr.

Dados

Notícias

Ferramentas

Mercados

Comunidade

Recursos principais

Follow Feed

Fluxo de Opções

Monitor

MRSN Mersana Therapeutics Inc

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Notícias Mersana Therapeutics Inc

Seu Histórico Recente

Empresa

Negócios

Popular

Obter o aplicativo

Tendências Agora

Rankings

Dados

Notícias

Ferramentas

Mercados

Comunidade

Recursos principais

Follow Feed

Fluxo de Opções

Monitor

MRSN Mersana Therapeutics Inc

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Notícias Mersana Therapeutics Inc

Seu Histórico Recente

Empresa

Negócios

Popular

Obter o aplicativo